Kisqali

Postmenopause, Breast, Metastatic Breast Cancer
Treatment
5 FDA approvals
9 Active Studies for Kisqali

What is Kisqali

RibociclibThe Generic name of this drug
Treatment SummaryRibociclib is a medication used to slow the growth of cancer cells. It works by targeting proteins called cyclin-dependent kinase 4 and 6 (CDK4/6) which control how fast cancer cells divide. By blocking these proteins, ribociclib helps prevent cancer cells from reproducing uncontrollably and spreading. The drug was approved by the FDA in 2017 and is known by the brand name Kisqali.
Kisqaliis the brand name
image of different drug pills on a surface
Kisqali Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Kisqali
Ribociclib
2017
6

Approved as Treatment by the FDA

Ribociclib, commonly known as Kisqali, is approved by the FDA for 5 uses like Postmenopause and Advanced Breast Cancer .
Postmenopause
Used to treat Postmenopausal in combination with null
Advanced Breast Cancer
Used to treat Advanced Breast Cancer in combination with null
Metastatic Breast Cancer
Used to treat Metastatic Breast Cancer in combination with null
Metastatic Breast Cancer
Used to treat Metastatic Breast Cancer in combination with null
Breast
Used to treat Advanced Breast Cancer in combination with null

Effectiveness

How Kisqali works in the bodyRibociclib is a drug used to treat cancer by blocking a specific type of enzyme found in some types of tumors. This enzyme, called cyclin-dependent kinase 4 and 6 (CDK4/6), helps the tumor to grow. Ribociclib is able to stop this enzyme from working, which prevents the growth of the tumor. It also prevents the tumor cells from reproducing, which helps to keep the tumor from spreading.

When to interrupt dosage

The recommended measure of Kisqali is contingent upon the ascertained condition, for example Metastatic Breast Cancer, Breast and Postmenopause. The dosage likewise vacillates as per the approach of delivery (e.g. Oral or Tablet, film coated) specified in the table beneath.
Condition
Dosage
Administration
Breast
, 200.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Metastatic Breast Cancer
, 200.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral
Postmenopause
, 200.0 mg
, Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral

Warnings

There are 20 known major drug interactions with Kisqali.
Common Kisqali Drug Interactions
Drug Name
Risk Level
Description
(R)-warfarin
Major
The metabolism of (R)-warfarin can be decreased when combined with Ribociclib.
(S)-Warfarin
Major
The metabolism of (S)-Warfarin can be decreased when combined with Ribociclib.
1,2-Benzodiazepine
Major
The metabolism of 1,2-Benzodiazepine can be decreased when combined with Ribociclib.
3,5-diiodothyropropionic acid
Major
The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Ribociclib.
5-androstenedione
Major
The metabolism of 5-androstenedione can be decreased when combined with Ribociclib.
image of a doctor in a lab doing drug, clinical research

Kisqali Novel Uses: Which Conditions Have a Clinical Trial Featuring Kisqali?

94 active clinical trials are currently assessing the potential of Kisqali to provide therapeutic benefit in Metastatic Breast Cancer, Postmenopausal Women and Breast Diseases.
Condition
Clinical Trials
Trial Phases
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
Breast
0 Actively Recruiting
Postmenopause
8 Actively Recruiting
Phase 2, Not Applicable, Phase 1

Kisqali Reviews: What are patients saying about Kisqali?

5Patient Review
12/10/2021
Kisqali for Hormone Receptor (HR)-Positive, HER2-Negative Advanced Breast Cancer in Woman
I've been using this treatment since May 2017 and it's working great! I have experienced some hair thinning and fatigue, but those are the only side effects so far.
5Patient Review
8/20/2019
Kisqali for Hormone Receptor (HR)-Positive, HER2-Negative Advanced Breast Cancer in Woman
Kisqali has been working great for me- I've had seven cycles of it and my PET/CT scan shows no cancer!
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about kisqali

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug Kisqali used for?

"KISQALI® is a prescription medicine that is used to treat adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. The cancer must have gotten worse or has spread to other parts of the body (metastatic) in order for KISQALI® to be prescribed. It is usually taken in combination with an aromatase inhibitor as the first hormonal based therapy for postmenopausal women or with fulvestrant."

Answered by AI

Is Kisqali a chemotherapy?

"KISQALI is not a chemotherapeutic drug, but a targeted therapy that inhibits substances that contribute to cancer cell growth. Targeted therapies can harm both cancerous and healthy cells."

Answered by AI

How much longer do you live on Kisqali?

"The median overall survival rate for those taking KISQALI was not reached at the 39 month check-in, as opposed to the 40 months check-in for those taking placebo. Results at the 56-month observational check-in showed that the median overall survival rate for those taking KISQALI in combination with fulvestrant was 53.7 months, as opposed to 41.5 months for those taking placebo and fulvestrant."

Answered by AI

Clinical Trials for Kisqali

Have you considered Kisqali clinical trials? We made a collection of clinical trials featuring Kisqali, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top